Richard Law
Stock Analyst at Goldman Sachs
(0.16)
# 4,470
Out of 5,150 analysts
76
Total ratings
16.67%
Success rate
-14.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Neutral | $65 → $95 | $95.09 | -0.09% | 1 | Mar 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sell | $2 → $3 | $4.94 | -39.27% | 4 | Mar 2, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $30 → $34 | $29.91 | +13.67% | 4 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $17.98 | -44.38% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $22.53 | +24.28% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $40.15 | +66.87% | 2 | Jan 12, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $26 → $38 | $24.69 | +53.91% | 7 | Dec 11, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $104.00 | +29.81% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $24.45 | +18.61% | 2 | Oct 30, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $28.61 | +81.75% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $30 | $30.56 | -1.82% | 4 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $3 | $5.80 | -48.28% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $32.55 | -7.83% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $18.58 | -40.80% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $28.06 | +67.53% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $60.25 | +4.56% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $86.51 | -57.23% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $13.76 | +452.33% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.28 | +514.04% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $13.91 | +338.53% | 4 | May 8, 2023 |
Protagonist Therapeutics
Mar 3, 2026
Maintains: Neutral
Price Target: $65 → $95
Current: $95.09
Upside: -0.09%
Rocket Pharmaceuticals
Mar 2, 2026
Maintains: Sell
Price Target: $2 → $3
Current: $4.94
Upside: -39.27%
Celldex Therapeutics
Mar 2, 2026
Maintains: Neutral
Price Target: $30 → $34
Current: $29.91
Upside: +13.67%
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $17.98
Upside: -44.38%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $22.53
Upside: +24.28%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $40.15
Upside: +66.87%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $26 → $38
Current: $24.69
Upside: +53.91%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $104.00
Upside: +29.81%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $24.45
Upside: +18.61%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $28.61
Upside: +81.75%
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $30.56
Upside: -1.82%
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.80
Upside: -48.28%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $32.55
Upside: -7.83%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $18.58
Upside: -40.80%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $28.06
Upside: +67.53%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $60.25
Upside: +4.56%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $86.51
Upside: -57.23%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $13.76
Upside: +452.33%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.28
Upside: +514.04%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $13.91
Upside: +338.53%